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eliminate in-stent restenosis in selected simple lesions (FIM. RAVEL trials). The aim of 
this study is to investigate the efficacy of SES in the treatment of bifurcation lesions. 
Methods: Since ld” April 2002 it is the policy of our institution to utilize the SES as a 
device of choice for all percutaneous interventions, with no clinical or anatomical exclu- 
sion criteria. The patients with bifurcation lesions are being included in this study. The fol- 
low-up angiography will be performed at 6 months after procedure. Results: Up to 161h 
August 2002, 44 patients with 44 bifurcation lesions have been treated with SES. The 
mean age was 61 years old and 13 patients (29.5%) were diabetic. All patients under- 
went SES deployment in both vessels. The baseline QCA results are present in the table. 
So far, there has been one target lesion revascularization 5 weeks after procedure, how- 
ever it is noteworthy that the restenosis occurred at the ostium of a side branch that was 
not covered with SES. The clinical outcomes and follow-up QCA results will be available 
at the time of presentation.Conclusions In this study, the impact of sirolimus-eluting 
stents on the outcome of patients with bifurcation lesions in the “real world” experience 
will be reported. 
Parent vessel side branch 
Pre reference diameter (mm) 2.84 - 0.56 2.31 - 0.54 
Pre minimum lumen diameter (mm) 0.76 - 0.59 0.65 - 0.50 
Post feference diameter (mm) 2.66 - 0.56 2.33 - 0.54 
Postminimum lumen diameter(mm) 2.36 -0.54 1.98 - 0.54 
1030-I 81 The Frequency and Consequences of Angiographic 
Aneurysms After Sirolimus-Eluting Stents: Results from 
SlRliJS 
Martin B. Leon, Jeffrey W. Moses, Giora Weiss, Paul S. Teirstein. Peter Fitzgerald, David 
R. Holmes, Jeffrey J. Popma. Cardiovascular Research Foundation, New York, NY 
Background: Angiographic aneurysms are observed after control bare metal stems 
(CS) in < 1% of pts and thusfar haven’t been associated with deleterious clinical out- 
comes. The marked anti-proliferative effects of sirolimus-eluting sterns (SES) raise con- 
cerns regarding potential vessel wall thinning and an increase in aneurysm formation. 
Methods: In the randomized double-blind SIRIUS trial (1058 pts), 8-month angiographic 
follow-up (FU) was obtained in 66% (702 pts). Angiographic aneurysms were defined as 
treatment site vessel diameter 2 1.5X the normal reference diameter (either at baseline 
or at FU) and all patients were assessed for clinical events (up to 9 months). 
Results: Aneurysms were found at FU in 6 pts (0.9%); 4 pts with CS (1.1%) and 2 pts 
with SES (0.6%). In the 4 CS aneurysms 0 FU, 2 were present at baseline and 
morhphology was fusiform ectasia in 2 (both multiple stents), and eccentric focal (<IO 
mm length) outpouching in 2 (1 proximal to RCA stent). In the 2 SES aneurysms @ FU, 
none were present at baseline and morphology was fusiform ectasia in 1 (3 SES after 
long RCA dissection) and eccentric focal outpouching in 1 (within RCA SES). In the 1 
case of SES focal outpouching, IVUS exam revealed.clear incomplete apposition at FU 
(flush apposition at baseline) with positive remodeling. Although 2 pts with angiographic 
aneurysms in CS pts had Res at FU, no pt in either group had adverse clinical events 
(death, MI. or stem thrombosis) during FU. 
Conclusions: Results from the SIRIUS angiographic analysis indicate that aneurysms at 
FU are (1) extremely infrequent (- 1%) with both CS and SES; (2) commonly were 
present at baseline and often are seen as diffuse fusiform ectasia; (3) are not associated 
with important clinical events (9 months FU). Thus, there are no objective findings to sug- 
gest that SES confer added risk of aneurysm formation and subsequent clinical events, 
1030-l 82 Platelet Activation After Stenting With Heparin-Coated 
Versus Noncoated Stents 
Paul A. Gurbel, Kevin P. Bliden, Bonnie L. Hi&t, Sinai Center for Thrombosis Research, 
Baltimore, MD 
Objectives: The purpose of the study was to investigate the effect of heparin coating on 
platelet activation following coronary artery stenbng. Background: In animal models hep- 
arin coating reduces platelet aggregation induced by coronary stenting. However, 
reduced platelet activation has never been demonstrated in humans. Methods: In a pro- 
spective randomized study of 50 consecutive elective patients, platelet activation was 
analyzed by measuring aggregation and surface receptor expression at baseline and at 2 
hours, 24 hours, 5 and 30 days following implantation of either heparin-coated or non- 
coated Bx velocity stent(s). Results: Platelet activation as measured by 24 hour expres- 
sion ( mean fluorescence intensity) of active glycoprotein (GP) Ilb/llla, and total GP llbi 
Illa. was decreased following implantation of a hepadn coated stent as compared to bare 
stents (10.3 f 6.1 vs 6.7 * 2.1, p=.O14 for active GPllb/llla and 382*101 vs 306+ 88, 
p=.Ol for total GPllb/llla). A trend at 30 days post-stentlng of lower total (383&150 vs 
296*86, ~~07) and active GP Ilb/llla expression (10.3i6.9 vs. 7.5k2.9, p=.15) were also 
observed with the heparin-coated stent. Aggregation and stimulated p-selectin did not 
differ between stent types. Conclusion: Elective stenting wtth a heparin-coated stent is 
associated with less early expression of GP Ilb/llla on circulating platelets as compared 
to revascularization with a bare stent of the same design. These findings have direct 
implications on the risk of subacute thrombosis and deserve further investigation 
1030-l 83 Sirolimus-Eluting Stent for the Treatment of Bypass 
Graft Disease: The Initial U.S. Experience 
Marco A. Costa, Jeffrey W. Moses, Martin B. Leon, Paul S. Teirstetn, Steven Yakubov, 
Andrew J. Carter, Tim A. Fischell, Paul Gilmore, Theodore A. Bass, University of Florida, 
Jacksonville, FL 
Background: Stenting has provided limited success in the treatment of saphenous vein 
grafts (SVG) as in-stent restenosis (ISR) and adverse clinical events remain a challenge. 
While brachytherapy has offered clear benefit in this high-risk population, outcomes 
remain suboptimal. The efficacy of Sirolimus-eluting stents in native coronary arteries is 
proven, however its application in bypass grafts remains to be determined. We report the 
first series of patients in the United States with graft disease treated with sirolimus-eluting 
stents as part of the compassionate use SECURE trial. 
Methods: Compassionate use of sirolimus-eluting stenting was indicated for patients 
with a serious disease or condition for which there was no acceptable alternative treat- 
ment available. To date, 80 patients have been enrolled in the SECURE study. Follow-up 
agiography will be repeated in all patients with prior brachytherapy failure. 
Results: Nineteen patients with bypass graft disease have been enrolled so far. Patient 
characteristics include: mean age 65 years, male 91%. prior myccardial infarction 55%, 
smokers 82%, diabetes 9%, hypertension 91% and hyperlipidemia 91%. Twenty-two per- 
cent presented with unstable angina. All patients had previous angioplasty. Seventeen 
lesions were treated in 15 grafts analyzed to date. Nine target vessels underwent previ- 
ous brachytherapy. Bypassed vessels were: RCA 29%, LAD 36%, Circumflex 29%. oth- 
ers 7%. Mean reference vessel diameter was 3.16mm, lesion length was 15mm. Mean of 
1.5 stents were implanted in each graft. There were no deaths up to 30 days in the first 
11 patients. Adjudicated in-hospital and a-month updated data will be presented. 
Conclusion: Implantation of sirolimus-eluting stents in high-risk patients is feasible. This 
may represent an important treatment option for patients with bypass graft disease. 
1030-l 84 Use of the Sirolimus Drug-Eluting Stent for Real World 
Coronary Lesions The Milan Experience: Results of the 
First 400 Lesions 
Vassilis Spanos Goran Stankovic, Flavio Airoldi, Matteo Montorfano, Nicola Corvaja. 
Francesco Liistro, Alaide Chieffo, Maryuri Segura, Davide Tavano, Carlo Di Mario, 
Antonio Colombo, Centro Cuore Columbus, Milan, Italy, San Raffaele Hospital, Milan, 
Italy 
Background: Positive results from the use of the Sirolimus drug-eluting stent 
(CYPHERTM, Cordis) in clinical trials addressing selected lesions have been published. 
We reporl our experience with the use of the Cypher stent in everyday clinical practice. 
Methods: We included all lesions treated with the Cypher stent in Milan between 15 of 
April and 30 of August 2002. Major adverse cardiac events (MACE) were defined as 
death, Q-wave myocardial infarction or target lesion revascularizatron. 
Results: Cypher stents were implanted in 217 patients (71% consecutive) to treat 418 
lesions. Three hundred fifty-three (84.5%) lesions were complex (ACClAHA classification 
82 or higher); 85 (20.3%) were in-stent restenosis and 42 (10.0%) chronic total occlu- 
sions. We utilized 2.2t1.6 Cypher stents per procedure (1.2~0.5 per lesion). Intravascu- 
lar ultrasound guidance was used in 67 (16.0%) lesions. The reference vessel size was 
2.8*0.5mm, the minimal lumen diameter (MLD) 0.79*0.48mm and the mean lesion 
length 18.5+13.8mm. 
The total length of Cypherstents used per lesion was 28.0+16.2mm. The maximum infla- 
tion pressure used was 15.7+3.4 atm and the balloon to artery ratio 1.1*0.3. The post- 
procedure MLD was 2.81*0.47mm, resulting in acute gain of 2.0*0.6mm. 
The clinical success rate was 99%. One patient required urgent coronary artery bypass 
surgery and died the next day and one had a Q-wave myocardial infarction during the 
procedure. 
Clinical follow-up at 1.720.5 months has been completed in 176 patients (97.8%) without 
detection of any other MACE. Six-month clinical follow-up will be available at the time of 
presentabon. Follow-up coronary angiography is planned for all patients nine months 
post-procedure and it is estimated to be accomplished in about 250 lesions at the time of 
presentation. Conclusions: The implantation of Cypher stents in “real world lesions”, 
aiming to completely cover the diseased segment, results in high stented vessel lengths. 
Thirly days complications are low without an increase in thrombosis, despite usage of 
long and multiple stents. We will see if follow-up results are in accordance with prior find- 
ings in less complex lesions. 
1030-l 85 Is There Any Arterial Toxic Effect After Overlapping 
Siroiimus-Eluting Stents? 
Alexandre A. Abizaid, Juan S. Munoz, Ana C. Seixas, Andrea S. Abizaid, Fausto Feres, 
Luiz A. Mattes, lbraim Pinto, Rodolfo Staico, Luiz F. Tanajura, Aurea J. Chaves, 
Marinella Centernero, Amanda Sousa, Gary S. Mints, Jose Eduardo M. Sousa, Institute 
Dante Pazzanese of Cardiology, Sao Paula, Brazil 
Background: Drug-eluting stents reduce first-time in-stent restenosis (ISR) and are 
being investigated as a treatment for ISR after bare-metal stenting. However, it remains 
unclear whether overlapping drug-eluting stents (and effectively doubling the drug dose) 
has a toxic effect on the vessel wall. 
Objective: The purpose of this study was to analyse the one-year IVUS findings after 2 
overlapping Sirolimus-eluting stems were implanted in patients with native artery ISR 
lesions. 
Methods: Cf 25 patients in the ISR Sirolimus registry, 8 had a lesion length requiring 2 
stents for full lesion coverage. Per protocol, these stents were implanted with a >l mm of 
overlap. Volumetric intravascular ultrasound (IVUS) was performed immediately and one 
year after implantation. 
